A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)

Natalie Banniettis,Jacek Wysocki,Leszek Szenborn,Wanatpreeya Phongsamart,Punnee Pitisuttithum,Mika Rämet,Peter Richmond,Yaru Shi,Ron Dagan,Lori Good,Melanie Papa,Robert Lupinacci,Richard McFetridge,Gretchen Tamms,Clay Churchill,Luwy Musey,Kara Bickham

Vaccine（2022）

Cited 4|Views11

No score

Abstract

•V114 catch-up vaccination was well tolerated in children 7 months–17 years of age.•V114 was immunogenic for all 15 serotypes, including those not contained in PCV13.•This supports pediatric V114 catch-up vaccination, regardless of prior PCV history.

Translated text

Key words

Pneumococcal conjugate vaccine,Catch-up vaccination,Safety,Immunogenicity,Pneumococcal disease

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined